|
United Therapeutics Corp Common
(UTHR)
|
12.1 |
$911M |
|
2.9M |
318.55 |
|
Madrigal Pharmaceuticals Common
(MDGL)
|
7.7 |
$576M |
|
2.1M |
280.16 |
|
Ascendis Pharma Sponsored ADR
(ASND)
|
7.6 |
$572M |
|
4.2M |
136.38 |
|
Argenx Se Sponsored ADR
(ARGX)
|
7.1 |
$533M |
|
1.2M |
430.04 |
|
Sarepta Therapeutics Common
(SRPT)
|
6.3 |
$474M |
|
3.0M |
158.00 |
|
Krystal Biotech Common
(KRYS)
|
6.0 |
$447M |
|
2.4M |
183.64 |
|
Apellis Pharmaceuticals Common
(APLS)
|
5.7 |
$426M |
|
11M |
38.36 |
|
Biomarin Pharmaceutical Common
(BMRN)
|
5.0 |
$375M |
|
4.6M |
82.33 |
|
Cerevel Therapeutics Hldng Common
(CERE)
|
4.1 |
$308M |
|
7.5M |
40.89 |
|
Spdr Series Trust - S&p Biotech Etf
(XBI)
|
3.7 |
$281M |
|
3.0M |
92.71 |
|
Amicus Therapeutics Common
(FOLD)
|
3.6 |
$272M |
|
27M |
9.92 |
|
Avidity Biosciences Common
(RNA)
|
3.5 |
$266M |
|
6.5M |
40.85 |
|
Arrowhead Pharmaceuticals Common
(ARWR)
|
3.1 |
$231M |
|
8.9M |
25.99 |
|
Xenon Pharmaceuticals Common
(XENE)
|
2.9 |
$221M |
|
5.7M |
38.99 |
|
Intra-cellular Therapies Common
(ITCI)
|
2.7 |
$206M |
|
3.0M |
68.49 |
|
Vera Therapeutics Common
(VERA)
|
2.1 |
$156M |
|
4.3M |
36.18 |
|
Moonlake Immunotherapeutics Class A Ord
(MLTX)
|
1.6 |
$122M |
|
2.8M |
43.97 |
|
Kymera Therapeutics Common
(KYMR)
|
1.5 |
$116M |
|
3.9M |
29.85 |
|
Alnylam Pharmceuticals Common
(ALNY)
|
1.3 |
$97M |
|
400k |
243.00 |
|
Iovance Biotherapeutics Common
(IOVA)
|
1.2 |
$94M |
|
12M |
8.02 |
|
Soleno Therapeutics Common
(SLNO)
|
1.1 |
$85M |
|
2.1M |
40.80 |
|
Merus N V Common
(MRUS)
|
1.1 |
$80M |
|
1.4M |
59.17 |
|
Syndax Pharmaceuticals Common
(SNDX)
|
1.1 |
$80M |
|
3.9M |
20.53 |
|
Biocryst Pharmaceuticals Common
(BCRX)
|
1.0 |
$78M |
|
13M |
6.18 |
|
Kura Oncology Common
(KURA)
|
1.0 |
$73M |
|
3.5M |
20.59 |
|
Ocular Therapeutix Common
(OCUL)
|
0.7 |
$55M |
|
8.1M |
6.84 |
|
Mannkind Corp Common
(MNKD)
|
0.6 |
$46M |
|
8.8M |
5.22 |
|
Vaxcyte Common
(PCVX)
|
0.6 |
$43M |
|
575k |
75.51 |
|
Spyre Therapeutics Common
(SYRE)
|
0.6 |
$43M |
|
1.8M |
23.51 |
|
Autolus Therapeutics Sponsored ADR
(AUTL)
|
0.6 |
$43M |
|
12M |
3.48 |
|
Taysha Gene Therapies Common
(TSHA)
|
0.6 |
$42M |
|
19M |
2.24 |
|
Ultragenyx Pharmaceutical Common
(RARE)
|
0.5 |
$34M |
|
830k |
41.10 |
|
Verrica Pharmaceuticals Common
|
0.4 |
$29M |
|
4.0M |
7.29 |
|
Tourmaline Bio Common
(TRML)
|
0.4 |
$29M |
|
2.2M |
12.86 |
|
Cg Oncology Common
(CGON)
|
0.3 |
$22M |
|
700k |
31.57 |
|
Monte Rosa Therapeutics Common
(GLUE)
|
0.2 |
$17M |
|
4.5M |
3.74 |
|
Bicycle Therapeutics Sponsored ADR
(BCYC)
|
0.2 |
$14M |
|
700k |
20.24 |
|
Aadi Biosciences Common
(WHWK)
|
0.1 |
$4.2M |
|
2.8M |
1.46 |
|
Dyne Therapeutics Common
(DYN)
|
0.1 |
$4.1M |
|
116k |
35.29 |
|
Adverum Biotechnologies Common
(ADVM)
|
0.0 |
$2.9M |
|
417k |
6.86 |
|
Neurogene Common
(NGNE)
|
0.0 |
$802k |
|
22k |
36.39 |